Effects of DPP-4 Inhibition on Calcium and Bone Metabolism in Type 2 Diabetes Mellitus
Primary Purpose
Type 2 Diabetes
Status
Withdrawn
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Sitagliptin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring diabetes, bone loss, Bone Density
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes mellitus.
- Hemoglobin A1c >6.5% and <10%.
- Estimated GFR greater than 60 mL per minute per meter squared.
- Between 18 and 70 years of age.
- On oral antihyperglycemic agents with stable dose at least for last 2 months.
- Females: minimum of two years postmenopausal, surgically sterile, or using an acceptable contraceptive regimen (OCP, IUD, double barrier, Depo-Provera or subcutaneous progestin implant) and negative urine pregnancy test at trial start.
Exclusion Criteria:
- Pregnancy, breast feeding or planning pregnancy during the study period
- Any medical condition expected to be terminal within one year
- Active mental illness or other condition which in the opinion of the investigator would prevent informed consent or adherence with study protocol
- Use of any PPAR agonist within three months prior to enrollment
- Daily insulin use
- Vitamin D level < 20
- Allergy or intolerance of sitagliptin or other DPP-4 inhibitor
- Use of DPP-4 inhibitor or GLP-1 analog within three months prior to enrollment
- Significant alcohol use defined as >3 standard servings of alcohol per day for men and >2 for women
- History of bariatric surgery in the last 3 years or planned bariatric surgery during the study period
- Receipt of another study drug within 30 days of screening.
Sites / Locations
- University of Missouri-Columbia: Diabetes Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Sitagliptin
Arm Description
Subjects will receive 90 tablets of 100mg sitagliptin
Outcomes
Primary Outcome Measures
Change in Bone Turnover
Secondary Outcome Measures
Full Information
NCT ID
NCT02444364
First Posted
May 11, 2015
Last Updated
May 30, 2017
Sponsor
University of Missouri-Columbia
1. Study Identification
Unique Protocol Identification Number
NCT02444364
Brief Title
Effects of DPP-4 Inhibition on Calcium and Bone Metabolism in Type 2 Diabetes Mellitus
Official Title
Pilot Project Evaluation of the DPP-4 Inhibition With Sitagliptin on Calcium and Bone Metabolism in Patients With Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
May 2017
Overall Recruitment Status
Withdrawn
Why Stopped
Funding withdrawn; no participants enrolled.
Study Start Date
May 2015 (undefined)
Primary Completion Date
January 2016 (Actual)
Study Completion Date
January 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Missouri-Columbia
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Participants will be persons with Type 2 Diabetes who are likely to have increased risk of bone fractures. The investigators believe this medication will enhance bone turnover.
The investigators will use DXA measurements to evaluate bone density before and after subjects take the medication.
Detailed Description
Type 2 Diabetes Mellitus (T2DM) is associated with an increased risk of bone fractures even when there is not decreased bone density via DXA measurements. This appears primarily related to impaired bone quality and abnormal bone architecture. Although the exact pathophysiologic mechanisms remain unclear, low bone turnover is considered one of the key defects. Emerging evidence suggests that dipeptidyl peptidase (DPP) inhibition is associated with improved bone quality and reduction in fracture risk.
While animal studies have shown an improvement in bone mineral density and trabecular architecture with sitagliptin treatment, no such studies in humans have yet been undertaken. We are proposing to extend these animal studies with a pilot clinical trial that seeks to use serum markers of bone turn-over and calcaneal quantitative ultrasound to evaluate the effect of DPP-4 inhibition on bone metabolism. Our hypothesis is that DPP-4 inhibition with sitagliptin will enhance bone turn over and quality in persons with T2DM.
This project project seeks to examine the impact of six months of therapy on sitagliptin, a DPP-4 inhibitor, on bone metabolism and bone quality in subjects with T2DM. The proposed study is intended to be a pilot investigation for providing preliminary data for submission of a more definitive national grant proposal with a larger patient population, blinded randomized control design and high resolution CT imaging of the lumbar spine.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
diabetes, bone loss, Bone Density
7. Study Design
Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sitagliptin
Arm Type
Experimental
Arm Description
Subjects will receive 90 tablets of 100mg sitagliptin
Intervention Type
Drug
Intervention Name(s)
Sitagliptin
Other Intervention Name(s)
Januvia
Intervention Description
Subjects will receive 90 tablets of 100mg sitagliptin
Primary Outcome Measure Information:
Title
Change in Bone Turnover
Time Frame
Six Months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes mellitus.
Hemoglobin A1c >6.5% and <10%.
Estimated GFR greater than 60 mL per minute per meter squared.
Between 18 and 70 years of age.
On oral antihyperglycemic agents with stable dose at least for last 2 months.
Females: minimum of two years postmenopausal, surgically sterile, or using an acceptable contraceptive regimen (OCP, IUD, double barrier, Depo-Provera or subcutaneous progestin implant) and negative urine pregnancy test at trial start.
Exclusion Criteria:
Pregnancy, breast feeding or planning pregnancy during the study period
Any medical condition expected to be terminal within one year
Active mental illness or other condition which in the opinion of the investigator would prevent informed consent or adherence with study protocol
Use of any PPAR agonist within three months prior to enrollment
Daily insulin use
Vitamin D level < 20
Allergy or intolerance of sitagliptin or other DPP-4 inhibitor
Use of DPP-4 inhibitor or GLP-1 analog within three months prior to enrollment
Significant alcohol use defined as >3 standard servings of alcohol per day for men and >2 for women
History of bariatric surgery in the last 3 years or planned bariatric surgery during the study period
Receipt of another study drug within 30 days of screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Muhammed T Sarmini, MD
Organizational Affiliation
University of Missouri-Columbia
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Missouri-Columbia: Diabetes Center
City
Columbia
State/Province
Missouri
ZIP/Postal Code
65212
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effects of DPP-4 Inhibition on Calcium and Bone Metabolism in Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs